RIA Advisory Group LLC Invests $342,000 in Perspective Therapeutics, Inc. (NYSE:CATX)

RIA Advisory Group LLC acquired a new position in Perspective Therapeutics, Inc. (NYSE:CATX) in the 3rd quarter, Holdings Channel reports. The institutional investor acquired 25,620 shares of the company’s stock, valued at approximately $342,000.

Other large investors have also made changes to their positions in the company. Sykon Capital LLC boosted its holdings in shares of Perspective Therapeutics by 4.7% during the 2nd quarter. Sykon Capital LLC now owns 37,932 shares of the company’s stock valued at $378,000 after purchasing an additional 1,717 shares during the last quarter. US Bancorp DE increased its stake in Perspective Therapeutics by 142.7% in the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after acquiring an additional 3,866 shares during the last quarter. nVerses Capital LLC bought a new stake in Perspective Therapeutics in the 3rd quarter worth approximately $57,000. Los Angeles Capital Management LLC bought a new position in shares of Perspective Therapeutics during the 3rd quarter valued at approximately $153,000. Finally, Victory Capital Management Inc. purchased a new stake in shares of Perspective Therapeutics during the 2nd quarter valued at about $117,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Price Performance

CATX traded down $1.04 on Friday, hitting $7.88. 1,849,338 shares of the company were exchanged, compared to its average volume of 695,032. The business has a 50-day moving average price of $12.55. Perspective Therapeutics, Inc. has a twelve month low of $2.28 and a twelve month high of $19.05.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on CATX. Oppenheimer restated an “outperform” rating and set a $22.00 price target on shares of Perspective Therapeutics in a report on Friday, October 11th. UBS Group began coverage on Perspective Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $20.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and set a $20.00 price target on shares of Perspective Therapeutics in a research note on Thursday, October 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Finally, Bank of America began coverage on Perspective Therapeutics in a research report on Thursday, July 25th. They issued a “buy” rating and a $24.00 target price on the stock. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $21.57.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.